MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

Core Viewpoint - MedX Health Corp. is proposing a non-brokered private placement of up to $5 million through the issuance of Series IV Convertible Loan Notes, aimed at accredited investors, to support its ongoing development and corporate purposes [1]. Group 1: Private Placement Details - The company plans to issue up to 100 Convertible Loan Notes, each with a face value of $50,000, bearing an interest rate of 6% per year, maturing on December 31, 2028 [1]. - The Series IV Notes can be converted into units at $0.10 per unit until the maturity date, with each unit consisting of one common share and half of a share purchase warrant [1]. - The placement is subject to a minimum subscription of $2.65 million and requires regulatory and stock exchange approvals [1]. Group 2: Use of Proceeds - Funds raised will be allocated to redeem any Series I Notes not surrendered for Series IV Notes, continue the development of the SIAscopy® technology on the DermSecure® platform, and support the launch of technology into the occupational health marketplace [1]. Group 3: Company Overview - MedX Health Corp. specializes in non-invasive skin screening and teledermatology, focusing on improving early detection of skin cancer through its proprietary SIAscopy® imaging technology [1]. - The company operates as an ISO 13485-certified medical device manufacturer and is involved in generating and analyzing skin health data using patented imaging and teledermatology systems [2].